Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03333915 2025-02-04

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase 1/2 Completed

128 enrolled 36 charts

Breast

Triple Negative Breast Neoplasms

NCT03914742 2025-01-14

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase 1/2 Completed

67 enrolled 18 charts

CNS

Glioblastoma

NCT02361723 2024-12-27

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

Phase 1 Completed

101 enrolled

Other solid neoplasm

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

200 enrolled

Rare Tumour

NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Phase 2 Completed

136 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

NCT03575065 2024-10-26

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2 Completed

88 enrolled 17 charts

Breast

HER2-negative Breast Cancer

NCT03994211 2024-10-26

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1 Completed

25 enrolled 33 charts

Other solid neoplasm

Solid Tumor

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

40 enrolled

Genitourinary

Locally Advanced Prostate Cancer

NCT05489926 2024-01-26

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Phase 2 Unknown

15 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase 2 Withdrawn

Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

NCT04985721 2023-03-15

IMPARP-HRD

Phase 2 Unknown

60 enrolled

Tumor-Agnostic

Neoplasms

NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Phase 2 Unknown

30 enrolled

Neoadjuvant Therapy

NCT05669768 2023-01-03

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Phase 2 Unknown

46 enrolled

Gynecologic

Ovarian Neoplasms

NCT05483543 2022-08-02

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Phase 2 Unknown

44 enrolled

Thoracic

Limited Stage Small Cell Lung Cancer

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT05327621 2022-04-14

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Phase 2 Unknown

50 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase 1 Completed

229 enrolled 46 charts

Other solid neoplasm

Solid Tumors

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2 Terminated

13 enrolled 11 charts

Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03933761 2021-08-10

PRECISE

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms